Abstract:Background/Objectives: The incidence of head and neck squamous cell carcinoma (HNSCC), currently ~800,000 cases per year worldwide, is rising. Radiotherapy remains a mainstay for the treatment of HNSCC, although inherent radioresistance, particularly in human papillomavirus (HPV)-negative disease subtypes, remains a significant barrier to effective treatment. Therefore, combinatorial strategies using drugs or inhibitors against specific cellular targets are necessary to enhance HNSCC radiosensitivity to lead to an improvement in patient outcomes. Given that radiotherapy acts through targeting and damaging DNA, a common strategy is to focus on enzymes within DNA-dependent cellular pathways, such as DNA damage repair. Methods: Here, we have employed a 3D spheroid model of HNSCC (FaDu) in combination with a targeted drug screen to identify novel radiosensitisers that suppress tumour growth. Results: We identified that histone deacetylases (HDACs) were prominent candidates, and subsequently identified that the HDAC inhibitors mocetinostat and pracinostat, as well as the combined HDAC–epidermal growth factor receptor inhibitor CUDC-101, were effective at radiosensitising cell models of HNSCC (FaDu, A253, UMSCC11b) through their impact on both spheroid growth and clonogenic survival assays. We also demonstrated that this combinatorial strategy leads to inhibition of the repair of DNA double-strand breaks through the neutral comet assay and γH2AX foci analysis using immunofluorescence microscopy, providing a mechanism of action through which HDAC inhibition functions in HNSCC radiosensitisation. Conclusions: We believe that this approach should be further investigated in preclinical models, in order to realise the full therapeutic potential of HDAC inhibition for the radiosensitisation of HNSCC, eventually leading to improved patient treatment efficacy and outcomes.

HDAC inhibitors: a new radiosensitizer for non-small-cell lung cancer.

HDAC Inhibitors Can Enhance Radiosensitivity of Head and Neck Cancer Cells through Suppressing DNA Repair

Effects of a novel HDAC6-selective inhibitor's radiosensitization on cancer cells

HDAC-an important target for improving tumor radiotherapy resistance

Histone deacetylase inhibitor use as a radiosensitizer in solid organ malignancies: a systematic review protocol

Research Progress in the mechanism of histone deacetylase inhibitors as radiosensitizers

Advances in targeting histone deacetylase for treatment of solid tumors

New Development of HDAC Inhibitors As Anti-Cancer Agents

Exploring the role of histone deacetylase inhibitors in cancer development and therapeutic potential

Sensitization to γ-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells

Hdac1/3 Dual Selective Inhibitors - New Therapeutic Agents For The Potential Treatment Of Cancer

Selective Histone Deacetylase Inhibitors with Anticancer Activity.

Mechanistic Sequence of Histone Deacetylase Inhibitors and Radiation Treatment: An Overview

Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy

Advances of histone deacetylases inhibitors as novel anti-cancer agents in clinical study

Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials.

FK228 sensitizes radioresistant small cell lung cancer cells to radiation

Research advances in the use of histone deacetylase inhibitors for epigenetic targeting of cancer.

Molecular probing and imaging of histone deacetylase inhibitors in cancer treatment.

Radiosensitization effect by HDAC inhibition improves NKG2D-dependent natural killer cytotoxicity in hepatocellular carcinoma

Targeting histone deacetylases for cancer therapy: Trends and challenges